The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

Aisner, Dara L.; Sholl, Lynette M.; Berry, Lynne D.; Rossi, Michael R.; Chen, Heidi; Fujimoto, Junya; Moreira, Andre L.; Ramalingam, Suresh S.; Villaruz, Liza C.; Otterson, Gregory A.; Haura, Eric; Politi, Katerina; Glisson, Bonnie; Cetnar, Jeremy; Garon, Edward B.; Schiller, Joan; Waqar, Saiama N.; Sequist, Lecia V.; Brahmer, Julie; Shyr, Yu; Kugler, Kelly; Wistuba, Ignacio I.; Johnson, Bruce E.; Minna, John D.; Kris, Mark G.; Bunn, Paul A.; Kwiatkowski, David J.

doi:10.1158/1078-0432.ccr-17-2289

Cited by 206Lung Cancer Treatments and MutationsCancer Genomics and DiagnosticsLung Cancer Diagnosis and Treatment

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

Open access

Aisner, Dara L., Sholl, Lynette M., Berry, Lynne D., Rossi, Michael R., Chen, Heidi, Fujimoto, Junya, Moreira, Andre L., Ramalingam, Suresh S. +19 more·2018·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-17-2289PMC PMC7008001

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Purpose: Multiplex genomic profiling is standard of care for patients with advanced lung adenocarcinomas. The Lung Cancer Mutation Consortium (LCMC) is a multi-institutional effort to identify and treat oncogenic driver events in patients with lung adenocarcinomas. Experimental Design: Sixteen U.S. institutions enrolled 1,367 patients with lung cancer in LCMC2; 904 were deemed eligible and had at least one of 14 cancer-related genes profiled using validated methods including genotyping, massively parallel sequencing, and IHC. Results: The use of targeted therapies in patients with EGFR, ERBB2, or BRAF p.V600E mutations, ALK, ROS1, or RET rearrangements, or MET amplification was associated with a survival increment of 1.5 years compared with those with such mutations not receiving targeted therapy, and 1.0 year compared with those lacking a targetable driver. Importantly, 60 patients with a history of smoking derived similar survival benefit from targeted therapy for alterations in EGFR/ALK/ROS1, when compared with 75 never smokers with the same alterations. In addition, coexisting TP53 mutations were associated with shorter survival among patients with EGFR, ALK, or ROS1 alterations. Conclusion: Patients with adenocarcinoma of the lung and an oncogenic driver mutation treated with effective targeted therapy have a longer survival, regardless of prior smoking history. Molecular testing should be performed on all individuals with lung adenocarcinomas irrespective of clinical characteristics. Routine use of massively parallel sequencing enables detection of both targetable driver alterations and tumor suppressor gene and other alterations that have potential significance for therapy selection and as predictive markers for the efficacy of treatment. Clin Cancer Res; 24(5); 1038–47. ©2017 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-2289

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

ROS1 fusion-positive LUAD have high concurrent CDKN2A loss (30.4%).
“both RET and ROS1 fusion-positive LUAD are characterized by high rates of concurrent CDKN2A loss (29.8% and 30.4% for RET and ROS1-rearranged tumors respectively)”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [131]
RET and ROS1 fusion-positive LUAD have relative paucity of TP53 mutations.
“relative paucity of TP53 mutations”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [131]
RET fusion-positive LUAD have high concurrent CDKN2A loss (29.8%).
“both RET and ROS1 fusion-positive LUAD are characterized by high rates of concurrent CDKN2A loss (29.8% and 30.4% for RET and ROS1-rearranged tumors respectively)”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [131]
ROS1 fusion-positive LUAD have high concurrent CDKN2B loss (17.7%).
“CDKN2B loss (25% and 17.7% respectively)”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [131]
RET fusion-positive LUAD have high concurrent CDKN2B loss (25%).
“CDKN2B loss (25% and 17.7% respectively)”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [131]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer Statistics, 2017.
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712 · see citing works
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · see citing works
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works
Self-citation
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · see citing works
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,442 · see citing works
Self-citation
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338 · see citing works
Self-citation
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · see citing works
Self-citation
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119 · see citing works
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964 · see citing works
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789 · see citing works
Self-citation
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724 · see citing works
Self-citation
p53 mutations in cancer
Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647 · see citing works
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Bergethon, K., Shaw, A. T., Ignatius Ou, S.-H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6345 · Cited by 1,555 · see citing works
Self-citation
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
Planchard, D., Smit, E. F., Groen, H. J. M., Mazières, J., Besse, B., Helland, Å., Giannone, V., D'amelio, A. M., Zhang, P., Mookerjee, B., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30679-4 · Cited by 1,360 · see citing works
Self-citation
RET, ROS1 and ALK fusions in lung cancer
Takeuchi, K., Soda, M., Togashi, Y., Suzuki, R., Sakata, S., Hatano, S., Asaka, R., Hamanaka, W., Ninomiya, H., Uehara, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2658 · Cited by 1,320 · see citing works
Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Chirieac, L. R., D’Amico, T. A., DeCamp, M. M., Dilling, T. J., Dobelbower, M. C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0050 · Cited by 1,305 · see citing works
Self-citation
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318290868f · Cited by 1,280 · see citing works
Self-citation
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
Cancer Genome Atlas Research Network, Campbell, J. D., Alexandrov, A., Kim, J., Wala, J., Berger, A. H., Pedamallu, C. S., Shukla, S. A., Guo, G., Brooks, A. N., et al. (2016) · Nature Genetics · doi:10.1038/ng.3564 · Cited by 1,200 · see citing works
Self-citation
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Barlési, F., Mazières, J., Merlio, J., Debieuvre, D., Mosser, J., Léna, H., Ouafik, L., Besse, B., Rouquette, I., Westeel, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00004-0 · Cited by 1,003 · see citing works
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
Planchard, D., Besse, B., Groen, H. J. M., Souquet, P.-J., Quoix, E., Baik, C. S., Barlesi, F., Kim, T. M., Mazieres, J., Novello, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30146-2 · Cited by 888 · see citing works
Self-citation
TP53 Mutations and Survival in Squamous-Cell Carcinoma of the Head and Neck
Poeta, M. L., Manola, J. B., Goldwasser, M. A., Forastiere, A. A., Benoit, N. E., Califano, J. A., Ridge, J. A., Goodwin, J. W., Kenady, D. E., Saunders, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073770 · Cited by 818 · see citing works
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
Frampton, G. M., Ali, S. M., Rosenzweig, M., Chmielecki, J., Lu, X., Bauer, T. M., Akimov, M., Bufill, J. A., Lee, C., Jentz, D., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0285 · Cited by 796 · see citing works
MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
Awad, M. M., Oxnard, G. R., Jackman, D. M., Savukoski, D. O., Hall, D., Shivdasani, P., Heng, J. C., Dahlberg, S. E., Janne, P. A., Verma, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4600 · Cited by 697 · see citing works
Self-citation
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Jordan, E. J., Kim, H. R., Arcila, M. E., Barron, D., Chakravarty, D., Gao, J., Chang, M. T., Ni, A., Kundra, R., Jonsson, P., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1337 · Cited by 643 · see citing works
Self-citation
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
Paik, P. K., Drilon, A. E. D. C., Fan, P., Yu, H. A., Rekhtman, N., Ginsberg, M. S., Borsu, L. A., Schultz, N. D., Berger, M. F., Rudin, C. M., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1467 · Cited by 575 · see citing works
RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer
Wang, R., Hu, H., Pan, Y., Li, Y., Ye, T., Li, C., Luo, X., Wang, L., Li, H., Zhang, Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.1477 · Cited by 549 · see citing works
Self-citation
A Genomics-Based Classification of Human Lung Tumors
Thomas, R. K., Buettner, R., & Wolf, J. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006802 · Cited by 508 · see citing works
Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer
Wu, J.-Y., Yu, C.-J., Chang, Y.-C., Yang, C.-H., Shih, J.-Y., & Yang, P.-C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3408 · Cited by 463 · see citing works
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Đačić, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J., Squire, J. A., et al. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.03.001 · Cited by 458 · see citing works
Self-citation
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
Planchard, D., Kim, T. M., Mazieres, J., Quoix, E., Riely, G., Barlesi, F., Souquet, P.-J., Smit, E. F., Groen, H. J. M., Kelly, R. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00077-2 · Cited by 453 · see citing works
Self-citation
Institutional implementation of clinical tumor profiling on an unselected cancer population
Sholl, L. M., Do, K., Shivdasani, P., Cerami, E., Dubuc, A. M., Kuo, F. C., Garcia, E. P., Jia, Y., Davineni, P., Abo, R. P., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87062 · Cited by 450 · see citing works
Self-citation
Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience
Sholl, L. M., Aisner, D. L., Varella-Garcia, M., Berry, L. D., Dias-Santagata, D., Wistuba, I. I., Chen, H., Fujimoto, J., Kugler, K., Franklin, W. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000516 · Cited by 430 · see citing works
Self-citation
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials
Meric-Bernstam, F., Brusco, L., Shaw, K., Horombe, C., Kopetz, S., Davies, M. A., Routbort, M., Piha-Paul, S. A., Janku, F., Ueno, N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.4165 · Cited by 424 · see citing works
Targeting RET in Patients With RET -Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
Gautschi, O. P., Milia, J., Filleron, T., Wolf, J., Carbone, D. P., Owen, D. H., Camidge, D. R., Narayanan, V., Doebele, R. C., Besse, B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.9352 · Cited by 364 · see citing works
Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations
Liu, X., Jia, Y., Stoopler, M. B., Shen, Y., Cheng, H., Chen, J., MANSUKHANI, M. M., Koul, S., Halmos, B., & Borczuk, A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.0674 · Cited by 350 · see citing works
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors
Kris, M. G., Camidge, D. R., Giaccone, G., Hida, T., Li, B. T., O'Connell, J., Taylor, I., Zhang, H., Arcila, M. E., Goldberg, Z., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv186 · Cited by 334 · see citing works
Self-citation
Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung
Spigel, D. R., Edelman, M. J., O'Byrne, K. J., Paz-Ares, L. G., Mocci, S., Phan, S. C., Shames, D. S., Smith, D., Yu, W., Paton, V. E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.2160 · Cited by 332 · see citing works
Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).
Camidge, D. R., Ou, S. I., Shapiro, G. I., Otterson, G. A., Villaruz, L. C., Villalona-Calero, M. A., Iafrate, A. J., Varella‐Garcia, M., Đačić, S., Cardarella, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8001 · Cited by 256 · see citing works
Self-citation
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
Patnaik, A., Appleman, L. J., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Weiss, G. J., Sachdev, J. C., Chadha, M. K., Fulk, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw282 · Cited by 240 · see citing works
Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers
Li, C., Fang, R., Sun, Y., Han, X., Li, F., Gao, B., Iafrate, A. J., Liu, X.-Y., Pao, W. J., Chen, H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028204 · Cited by 230 · see citing works
Self-citation
Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)
Labbé, C., Cabanero, M., Korpanty, G. J., Tomasini, P., Doherty, M. K., Mascaux, C., Jao, K., Pitcher, B., Wang, R., Pintilie, M., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.06.014 · Cited by 230 · see citing works
High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer
Go, H., Jeon, Y. K., Park, H. J., Sung, S.-W., Seo, J., & Chung, D. H. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181ce3d1d · Cited by 217 · see citing works
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
Kobayashi, Y., Togashi, Y., Yatabe, Y., Mizuuchi, H., Jangchul, P., Kondo, C., Shimoji, M., Sato, K., Suda, K., Tomizawa, K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1046 · Cited by 203 · see citing works
Mutations in TP53 , PIK3CA , PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes
VanderLaan, P. A., Rangachari, D., Mockus, S. M., Spotlow, V., Reddi, H. V., Malcolm, J., Huberman, M. S., Joseph, L. J., Kobayashi, S. S., & Costa, D. B. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.01.011 · Cited by 188 · see citing works
Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer
Molina‐Vila, M. Á., Bertrán-Alamillo, J., Gascó, A., Mayo‐de‐las‐Casas, C., Sanchez-Ronco, M., Pujantell-Pastor, L., Bonanno, L., Favaretto, A. G., Cardona, A. F., Vergnenégre, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2391 · Cited by 181 · see citing works
Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung Cancer
Dziadziuszko, R., Wynes, M. W., Singh, S., Asuncion, B. R., Ranger‐Moore, J., Konopa, K., Rzyman, W., Szostakiewicz, B., Jassem, J., & Hirsch, F. R. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318240ca0d · Cited by 156 · see citing works
EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma
He, M., Capelletti, M., Nafa, K., Yun, C.-H., Arcila, M. E., Miller, V. A., Ginsberg, M. S., Zhao, B., Kris, M. G., Eck, M. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2361 · Cited by 149 · see citing works
Self-citation
Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
Koeppen, H., Yu, W., Zha, J., Pandita, A., Penuel, E. M., Rangell, L. K., Raja, R. G., Mohan, S., Patel, R., Desai, R. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1836 · Cited by 136 · see citing works
Self-citation
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the L ung C ancer M utation C onsortium
Villaruz, L. C., Socinski, M. A., Abberbock, S. R., Berry, L. D., Johnson, B. E., Kwiatkowski, D. J., Iafrate, A. J., Varella‐Garcia, M., Franklin, W. A., Camidge, D. R., et al. (2014) · Cancer · doi:10.1002/cncr.29042 · Cited by 127 · see citing works
Self-citation
EGFR Exon 18 Mutations in Lung Cancer：Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
祥久, 小. (2017) · Cited by 114 · see citing works
PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer
Lotan, T. L., Wei, W., Morais, C. L., Hawley, S. T., Fazli, L., Hurtado‐Coll, A., Troyer, D. A., McKenney, J. K., Simko, J. P., Carroll, P. R., et al. (2015) · European Urology Focus · doi:10.1016/j.euf.2015.07.005 · Cited by 76 · see citing works
Kinase gene fusions in defined subsets of melanoma
Turner, J. A., Couts, K. L., Sheren, J. E., Saichaemchan, S., Ariyawutyakorn, W., Avolio, I., Cabral, E., Glogowska, M., Amato, C. M., Robinson, S. E., et al. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12560 · Cited by 51 · see citing works
FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation
Administration, U. S. F. &. D. (2017) · Case Medical Research · doi:10.31525/fda1-ucm564331.htm · Cited by 10 · see citing works

Flagged first, then by citations

Research works printed but not linked: 1

[20]Villaruz LC, Socinski MA, Abberbock S,: Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer 121: 448– 56, 2015 25273224 PMC4305000

Sorted by citations

The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Nicholson, A. G., Tsao, M., Beasley, M. B., Borczuk, A., Brambilla, E. M., Cooper, W. A., Đačić, S., Jain, D., Kerr, K. M., Lantuéjoul, S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.003 · Cited by 1,606 · see citing works
Self-citation
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019 · see citing works
Review of precision cancer medicine: Evolution of the treatment paradigm
Tsimberidou, A. M., Fountzilas, E., Nikanjam, M., & Kurzrock, R. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102019 · Cited by 776 · see citing works
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
Oxnard, G. R., Hu, Y., Mileham, K. F., Husain, H., Costa, D. B., Tracy, P., Feeney, N., Sholl, L. M., Dahlberg, S. E., Redig, A. J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2969 · Cited by 686 · see citing works
Self-citation
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
Camidge, D. R., Doebele, R. C., & Kerr, K. M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0173-9 · Cited by 514 · see citing works
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden
Benayed, R., Offin, M. D., Mullaney, K. A., Sukhadia, P., Rios, K., Desmeules, P., Ptashkin, R. N., Won, H. H., Chang, J. C., Halpenny, D. F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0225 · Cited by 491 · see citing works
Self-citation
MET-dependent solid tumours — molecular diagnosis and targeted therapy
Guo, R., Luo, J., Chang, J. C., Rekhtman, N., Arcila, M. E., & Drilon, A. E. D. C. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0377-z · Cited by 329 · see citing works
Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis
Planchard, D., Besse, B., Groen, H. J. M., Hashemi, S. M. S., Mazières, J., Kim, T. M., Quoix, É., Souquet, P.-J., Barlési, F., Baik, C. S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.08.011 · Cited by 274 · see citing works
Self-citation
Deep learning classification of lung cancer histology using CT images
Chaunzwa, T. L., Hosny, A., Xu, Y., Shafer, A., Diao, N., Lanuti, M. D., Christiani, D. C., Mak, R. H., & Aerts, H. J. W. L. (2021) · Scientific Reports · doi:10.1038/s41598-021-84630-x · Cited by 269 · see citing works
Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience
Osta, B. E. E., Behera, M., Kim, S., Berry, L. D., Sica, G., Pillai, R. N., Owonikoko, T. K., Kris, M. G., Johnson, B. E., Kwiatkowski, D. J., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.01.020 · Cited by 229 · see citing works
Self-citation
The PI3K/Akt/mTOR pathway in lung cancer; oncogenic alterations, therapeutic opportunities, challenges, and a glance at the application of nanoparticles
Sanaei, M., Razi, S., Pourbagheri‐Sigaroodi, A., & Bashash, D. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101364 · Cited by 204 · see citing works
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
Kron, A., Alidousty, C., Scheffler, M., Merkelbach-Bruse, S., Seidel, D., Riedel, R., Ihle, M. A., Michels, S., Nogova, L., Fassunke, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy333 · Cited by 197 · see citing works
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer
Blumenthal, G. M., Bunn, P. A., Chaft, J. E., McCoach, C. E., Perez, E. A., Scagliotti, G. V., Carbone, D. P., Aerts, H. J. W. L., Aisner, D. L., Bergh, J. C. S., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.017 · Cited by 187 · see citing works
Self-citation
Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer
Fois, S. S., Paliogiannis, P., Zinellu, A., Fois, A. G., Cossu, A., & Palmieri, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020612 · Cited by 187 · see citing works
MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium
Guo, R., Berry, L. D., Aisner, D. L., Sheren, J. E., Boyle, T. A., Bunn, P. A., Johnson, B. E., Kwiatkowski, D. J., Drilon, A. E. D. C., Sholl, L. M., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.06.009 · Cited by 172 · see citing works
Self-citation
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
Leonetti, A., Facchinetti, F., Rossi, G., Minari, R., Conti, A., Friboulet, L., Tiseo, M., & Planchard, D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.006 · Cited by 169 · see citing works
Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics
Padinharayil, H., Varghese, J., John, M. C., Rajanikant, G. K., Wilson, C. M., Al-Yozbaki, M., Renu, K., Dewanjee, S., Sanyal, R., Dey, A., et al. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.023 · Cited by 167 · see citing works
Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy
Wang, Q., Li, M., Yang, M., Yang, Y., Song, F., Zhang, W., Li, X., & Chen, K. (2020) · Aging · doi:10.18632/aging.102814 · Cited by 162 · see citing works
Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis
Qin, K., Hou, H., Yu, L., & Zhang, X. (2020) · BMC Cancer · doi:10.1186/s12885-020-06805-5 · Cited by 160 · see citing works
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
Michels, S. Y. F., Massutí, B., Schildhaus, H., Franklin, J. G., Sebastian, M., Felip, E., Grohé, C., Rodríguez‐Abreu, D., Abdulla, D. S. Y., Bischoff, H. G., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.03.020 · Cited by 132 · see citing works
Transcriptomics and solid tumors: The next frontier in precision cancer medicine
Tsimberidou, A. M., Fountzilas, E., Bleris, L. G., & Kurzrock, R. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.09.007 · Cited by 114 · see citing works
Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases
Volckmar, A., Leichsenring, J., Kirchner, M., Christopoulos, P., Neumann, O., Budczies, J., de Oliveira, C. M. M., Rempel, E., Buchhalter, I., Brandt, R., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32133 · Cited by 102 · see citing works
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives
Ferrara, M. G., Noia, V. D., D’Argento, E., Vita, E., Damiano, P., Cannella, A., Ribelli, M., Pilotto, S., Milella, M., Tortora, G., et al. (2020) · Cancers · doi:10.3390/cancers12051196 · Cited by 96 · see citing works
Identification of a highly lethal V3 + TP53 + subset in ALK + lung adenocarcinoma
Christopoulos, P., Kirchner, M., Bozorgmehr, F., Endris, V., Elsayed, M., Budczies, J., Ristau, J., Penzel, R., Herth, F. J. F., Heußel, C. P., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31893 · Cited by 93 · see citing works
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)
Griesinger, F., Eberhardt, W., Nusch, A., Reiser, M., Zahn, M., Maintz, C., Bernhardt, C., Losem, C. J., Stenzinger, A., Heukamp, L. C., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.10.012 · Cited by 93 · see citing works
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
Canale, M., Andrikou, K., Priano, I., Cravero, P., Pasini, L., Urbini, M., Delmonte, A., Crinò, L., Bronte, G., & Ulivi, P. (2022) · Cancers · doi:10.3390/cancers14051143 · Cited by 93 · see citing works
Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations
Jamme, P., Fernandes, M., Copin, M., Descarpentries, C., Escande, F., Morabito, A., Grégoire, V., Jamme, M., Baldacci, S., Tulasne, D., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.027 · Cited by 91 · see citing works
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping
Zugazagoitia, J., Ramos, I. C., Trigo, J. M., Palka, M., Gómez‐Rueda, A., Lewintre, E. J., Camps, C., Isla, D., Iranzo, P., Ponce-Aix, S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy512 · Cited by 83 · see citing works
Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations
Rich, T. A., Reckamp, K. L., Chae, Y. K., Doebele, R. C., Iams, W. T., Oh, M. S., Raymond, V. M., Lanman, R. B., Riess, J. W., Stinchcombe, T. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4049 · Cited by 83 · see citing works
Combined model integrating deep learning, radiomics, and clinical data to classify lung nodules at chest CT
Lin, C.-Y., Guo, S., Lien, J.-J. J., Lin, W.-T., Liu, Y., Lai, C., Hsu, I.-L., Chang, C., & Tseng, Y. (2023) · La radiologia medica · doi:10.1007/s11547-023-01730-6 · Cited by 80 · see citing works
Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non–Small-Cell Lung Cancer
Aggarwal, C., Davis, C. W., Mick, R., Thompson, J. C., Ahmed, S., Jeffries, S., Bagley, S. J., Gabriel, P. E., Evans, T. L., Bauml, J. M., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00107 · Cited by 79 · see citing works
Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy
Kron, A., Scheffler, M., Heydt, C., Ruge, L., Schaepers, C., Eisert, A., Merkelbach‐Bruse, S., Riedel, R. F., Nogová, L., Fischer, R. N., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.017 · Cited by 71 · see citing works
Genetic instability and recurrent MYC amplification in ALK‐translocated NSCLC: a central role of TP53 mutations
Alidousty, C., Baar, T., Martelotto, L. G., Heydt, C., Wagener, S., Fassunke, J., Duerbaum, N., Scheel, A. H., Frank, S., Holz, B., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5110 · Cited by 69 · see citing works
MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities
Qin, K., Hong, L., Zhang, J. J., & Le, X. (2023) · Cancers · doi:10.3390/cancers15030612 · Cited by 66 · see citing works
Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer
Yu, Y., Ou, Q., Wu, X., Bao, H., Ding, Y., Shao, Y. W., & Lü, S. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.11.024 · Cited by 65 · see citing works
Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung Cancer
Kim, E. K., Kim, K., Lee, C. Y., Kim, S., Chang, S. H., Cho, B. C., & Shim, H. S. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.10.004 · Cited by 63 · see citing works
Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions
Choudhury, N. J., Schoenfeld, A. J., Flynn, J. R., Falcon, C. J., Rizvi, H. A., Rudin, C. M., Kris, M. G., Arcila, M. E., Heller, G., Yu, H. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4650 · Cited by 59 · see citing works
Self-citation
FOX-A1 Contributes to Acquisition of Chemoresistance in Human Lung Adenocarcinoma via Transactivation of SOX5
Chen, D., Wang, R., Chen, Y., Cao, F., Zhang, X., Yan, F., Chen, L., Zhu, H., Yu, Z., & Feng, J. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.05.046 · Cited by 59 · see citing works
ILT3 promotes tumor cell motility and angiogenesis in non-small cell lung cancer
Li, J., Gao, A., Zhang, F., Wang, S., Wang, J., Wang, J., Han, S., Yang, Z., Chen, X., Fang, Y., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.10.048 · Cited by 55 · see citing works
Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Oh, S. Y., Lee, Y. W., Lee, E. J., Kim, J. H., Park, Y., Heo, S. G., Yu, M. R., Hong, M. H., DaSilva, J. O., Daly, C., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2180 · Cited by 51 · see citing works
Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial
Bertucci, F., Gonçalvès, A., Guillé, A., Adélaı̈de, J., Garnier, S., Carbuccia, N., Billon, E., Finetti, P., Sfumato, P., Monneur, A., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00897-9 · Cited by 51 · see citing works
Deep learning of cell spatial organizations identifies clinically relevant insights in tissue images
Wang, S., Rong, R., Zhou, Q., Yang, D. M., Zhang, X., Zhan, X., Bishop, J. A., Chi, Z., Wilhelm, C., Zhang, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43172-8 · Cited by 50 · see citing works
Self-citation
Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK‐rearranged non‐small‐cell lung cancer
Song, P., Zhang, F., Li, Y., Yang, G., Li, W., Ying, J., & Gao, S. (2019) · Cancer Medicine · doi:10.1002/cam4.2043 · Cited by 50 · see citing works
Prognostic and predictive biomarkers in non-small cell lung carcinoma
Odintsov, I., & Sholl, L. M. (2023) · Pathology · doi:10.1016/j.pathol.2023.11.006 · Cited by 46 · see citing works
Self-citation
Cancer driver gene and non-coding RNA alterations as biomarkers of brain metastasis in lung cancer: A review of the literature
Karimpour, M., Gavgani, R. R., Maydanchi, M., Rajabi, A., Azizi, F., & Saber, A. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112190 · Cited by 46 · see citing works
Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer
Wolf, J. M., Helland, Å., Oh, I., Migliorino, M. R., Dziadziuszko, R., Wrona, A., de Castro, J., Mazières, J., Griesinger, F., Chlistalla, M., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2021.100333 · Cited by 45 · see citing works
Genetic differences between smokers and never-smokers with lung cancer
Kuśnierczyk, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1063716 · Cited by 45 · see citing works
Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis
Kästner, A., Kron, A., van den Berg, N., Moon, K., Scheffler, M., Schillinger, G., Pelusi, N., Hartmann, N., Rieke, D. T., Stephan-Falkenau, S., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100788 · Cited by 45 · see citing works
Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations
Passaro, A., Attili, I., Rappa, A., Vacirca, D., Ranghiero, A., Fumagalli, C., Guarize, J., Spaggiari, L., de Marinis, F., Barberis, M. C. P., et al. (2021) · Cancers · doi:10.3390/cancers13092172 · Cited by 45 · see citing works
Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases
Guo, R., Schreyer, M., Chang, J. C., Rothenberg, S. M., Henry, D., Cotzia, P., Kris, M. G., Rekhtman, N., Young, R. J., Hyman, D. M., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00021 · Cited by 44 · see citing works
Self-citation
Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer
Tao, H., Shi, L., Zhou, A., Li, H., Gai, F., Huang, Z., Che, N., & Liu, Z. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.09.012 · Cited by 44 · see citing works
Defining molecular risk in ALK+ NSCLC
Christopoulos, P., Budczies, J., Kirchner, M., Dietz, S., Sültmann, H., Thomas, M., & Stenzinger, A. (2019) · Oncotarget · doi:10.18632/oncotarget.26886 · Cited by 41 · see citing works
Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival
Christopoulos, P., Dietz, S., Kirchner, M., Volckmar, A., Endris, V., Neumann, O., Ogrodnik, S. J., Heußel, C. P., Herth, F. J. F., Eichhorn, M., et al. (2019) · Cancers · doi:10.3390/cancers11010124 · Cited by 39 · see citing works
Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Digumarthy, S. R., Mendoza, D. P., Zhang, E. W., Lennerz, J. K., & Heist, R. S. (2019) · Cancers · doi:10.3390/cancers11122033 · Cited by 39 · see citing works
2020 Innovation-Based Optimism for Lung Cancer Outcomes
Schenk, E. L., Patil, T., Pacheco, J. M., & Bunn, P. A. (2020) · The Oncologist · doi:10.1002/onco.13590 · Cited by 36 · see citing works
Self-citation
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer
Michels, S. Y. F., Heydt, C., van Veggel, B. A. M. H., Deschler-Baier, B., Pardo, N., Monkhorst, K., Rüsseler, V., Stratmann, J., Griesinger, F., Steinhauser, S., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00210 · Cited by 36 · see citing works
Perioperative targeted therapy for oncogene-driven NSCLC
Liu, S. M., Zhang, J.-T., Zeng, K.-H., & Wu, Y.-L. L. C. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.05.007 · Cited by 34 · see citing works
The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies?
Pezzuto, F., Hofman, V., Bontoux, C., Fortarezza, F., Lunardi, F., Calabrese, F., & Hofman, P. M. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107249 · Cited by 34 · see citing works
Evolving roles of MET as a therapeutic target in NSCLC and beyond
Lee, J. B., Shim, J. S. G., & Cho, B. C. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01051-9 · Cited by 34 · see citing works
Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis
Breadner, D. A., Blanchette, P., Shanmuganathan, S., Boldt, G., & Raphael, J. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.04.011 · Cited by 30 · see citing works
FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma
King, G. T., & Javle, M. M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01100-3 · Cited by 30 · see citing works
Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer
Kauffmann-Guerrero, D. E., Kahnert, K., & Huber, R. M. (2020) · Drugs · doi:10.1007/s40265-020-01445-2 · Cited by 29 · see citing works
Clinicopathologic and genomic features of high-grade pattern and their subclasses in lung adenocarcinoma
Ahn, B., Yoon, S., Kim, D., Chun, S., Lee, G., Kim, H.-R., Jang, S. J., & Hwang, H. S. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.07.003 · Cited by 29 · see citing works
Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?
Hofman, V., Lassalle, S., Bence, C., Long-Mira, É., Nahon‐Estève, S., Heeke, S., Lespinet‐Fabre, V., Butori, C., Ilié, M., & Hofman, P. M. (2018) · Cancers · doi:10.3390/cancers10030070 · Cited by 28 · see citing works
Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients
Janke, F., Angeles, A. K., Riediger, A. L., Bauer, S., Reck, M., Stenzinger, A., Schneider, M. A., Muley, T., Thomas, M., Christopoulos, P., et al. (2022) · Clinical Epigenetics · doi:10.1186/s13148-022-01387-4 · Cited by 26 · see citing works
Statins may have double-edged effects in patients with lung adenocarcinoma after lung resection
Nishikawa, S., Menju, T., Takahashi, K., Miyata, R., Yoshikawa, T. F. C., Sonobe, M., Yoshizawa, A., Sabe, H., Sato, T. S., & Date, H. (2019) · Cancer Management and Research · doi:10.2147/cmar.s200819 · Cited by 26 · see citing works
Profiling the Mutational Landscape in Known Driver Genes and Novel Genes in African American Non–Small Cell Lung Cancer Patients
Lusk, C. M., Watza, D., Dyson, G. E., Craig, D., Ratliff, V., Wenzlaff, A. S., Lonardo, F., Bollig-Fischer, A. B., Bepler, G., Purrington, K. S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2439 · Cited by 25 · see citing works
Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer
Dalal, A. A., Guérin, A., Mutebi, A., & Culver, K. W. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1450261 · Cited by 24 · see citing works
Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance
Zugazagoitia, J., Gómez‐Rueda, A., Lewintre, E. J., Isla, D., Camps, C., Ramos, I., Trigo, J. M., Bernabé, R., Juan, Ó., Sánchez-Torres, J. M., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.032 · Cited by 24 · see citing works
Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung Cancer
Gregorc, V., Lazzari, C., Mandalà, M., Ippati, S., Bulotta, A., Cangi, M. G., Khater, A., Viganò, M. G., Mirabile, A., Pecciarini, L., et al. (2021) · Cancers · doi:10.3390/cancers13092023 · Cited by 23 · see citing works
The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review
Fulton-Ward, T., & Middleton, G. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.124 · Cited by 23 · see citing works
The prognostic impact of TP53 comutation in EGFR mutant lung cancer patients: a systematic review and meta-analysis
Zhang, R., Tian, P., Chen, B., Wang, T., & Li, W. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1585690 · Cited by 23 · see citing works
Integrating genetic mutations and expression profiles for survival prediction of lung adenocarcinoma
Song, Y., Chen, D., Zhang, X., Luo, Y., & Li, S. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13072 · Cited by 22 · see citing works
The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung Cancer
Gitlitz, B. J., Novello, S., Vavalà, T., Bittoni, M. A., Sable-Hunt, A. L., Pavlick, D. C., Hsu, R. C., Park, S., Chen, R., Cooke, M., et al. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100194 · Cited by 22 · see citing works
Self-citation
The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutations—The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and Concurrent Genetic Alterations
Tan, J., Hu, C., Deng, P., Wan, R., Cao, L., Li, M., Yang, H., Gu, Q., An, J., & Jiang, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.646577 · Cited by 22 · see citing works
Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers
Toor, O. M., Ahmed, Z., Bahaj, W., Boda, U., Cummings, L. S., McNally, M. E., Kennedy, K. F., Pluard, T., Hussain, A., Subramanian, J., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1015 · Cited by 22 · see citing works
TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib
Yu, R., Bai, H., Li, T., Gao, B., Han, J., Chang, G., Zhang, P., Fei, K., He, X., & Wang, J. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101163 · Cited by 22 · see citing works
Novel clinical trial designs emerging from the molecular reclassification of cancer
Nikanjam, M., Kato, S., Allen, T., Sicklick, J. K., & Kurzrock, R. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21880 · Cited by 21 · see citing works
KIF5B-RET fusion gene and its correlation with clinicopathological and prognosis features in lung cancer: a meta-analysis
Cong, X., Yang, L., Chen, C., & Liu, Z. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s186361 · Cited by 21 · see citing works
Domain-specific p53 mutants activate EGFR by distinct mechanisms exposing tissue-independent therapeutic vulnerabilities
Ho, T. L. F., Lee, M. Y., Goh, H. C., Ng, G. Y. N., Lee, J. J. H., Kannan, S., Lim, Y. T., Zhao, T., Lim, E. K. H., Phua, C. Z. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37223-3 · Cited by 21 · see citing works
Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testing procedures, burden, and treatments
Yang, M., Mandal, E., Liu, F. X., O'Hara, R. M., Lesher, B. A., & Sanborn, R. E. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1241402 · Cited by 21 · see citing works
Diagnostic and Predictive Immunohistochemistry for Non–Small Cell Lung Carcinomas
Hung, Y. P., & Sholl, L. M. (2018) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000206 · Cited by 21 · see citing works
Self-citation
Prognostic significance of mutant-allele tumor heterogeneity in uterine corpus endometrial carcinoma
Hou, Y., Li, T., Gan, W., Lv, S., Zeng, Z., Zheng, Y., Wang, W., & Yang, M. H. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.136 · Cited by 21 · see citing works
Intelligent classification of lung malignancies using deep learning techniques
Yadlapalli, P., Bhavana, D., & Suryanarayana, G. (2021) · International Journal of Intelligent Computing and Cybernetics · doi:10.1108/ijicc-07-2021-0147 · Cited by 20 · see citing works
Concurrent TP53 mutations predict a poor prognosis of EGFR‑mutant NSCLCs treated with TKIs: An updated systematic review and meta‑analysis
Lan, B., Zhao, N., Du, K., & Leng, B. (2022) · Oncology Letters · doi:10.3892/ol.2022.13504 · Cited by 20 · see citing works
Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer
Wang, S., Rong, R., Yang, D. M., Fujimoto, J., Bishop, J. A., Yan, S. X., Cai, L., Behrens, C., Berry, L. D., Wilhelm, C., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci160330 · Cited by 20 · see citing works
Self-citation
TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis
Jiang, B., Hu, L., Dong, D., Guo, Z., Wei, W., Wang, C., Shao, W., Ma, T., Chen, Y., Li, Q., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04924-7 · Cited by 20 · see citing works
Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non–Small Cell Lung Cancer: Implications for Precision Medicine
Lee, Y., Lee, B., Choi, Y., Kang, D., & Han, J. (2024) · Modern Pathology · doi:10.1016/j.modpat.2024.100490 · Cited by 19 · see citing works
Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
Liu, L., Kalyani, F. S., Yang, H., Zhou, C., Xiong, Y., Zhu, S., Yang, N., & Qu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.649766 · Cited by 19 · see citing works
Use of Low-Frequency Driver Mutations Detected by Cell-Free Circulating Tumor DNA to Guide Targeted Therapy in Non–Small-Cell Lung Cancer: A Multicenter Case Series
Jacobs, M. T., Mohindra, N. A., Shantzer, L., Chen, I. L., Phull, H. S., Mitchell, W., Raymond, V. M., Banks, K. C., Nagy, R. J., Lanman, R. B., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00318 · Cited by 18 · see citing works
Nicotinamide N-Methyltransferase Remodeled Cell Metabolism and Aggravated Proinflammatory Responses by Activating STAT3/IL1β/PGE2 Pathway
Yang, C., Wang, T., Zhu, S., Zong, Z., Luo, C., Zhao, Y., Liu, J., Li, T., Liu, X., Liu, C., et al. (2022) · ACS Omega · doi:10.1021/acsomega.2c04286 · Cited by 18 · see citing works
Molecular profiling and identification of prognostic factors in Chinese patients with small bowel adenocarcinoma
Pan, H., Cheng, H., Wang, H., Ge, W., Yuan, M., Jiang, S., Wan, X., Dong, Y., Liu, Z., Zhao, R., et al. (2021) · Cancer Science · doi:10.1111/cas.15119 · Cited by 17 · see citing works
Implication of mTOR Signaling in NSCLC: Mechanisms and Therapeutic Perspectives
Gargalionis, A. N., Papavassiliou, K. A., & Papavassiliou, A. G. (2023) · Cells · doi:10.3390/cells12152014 · Cited by 15 · see citing works
TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer
Costa, D. B. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy339 · Cited by 15 · see citing works
PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non–small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors
Ferrara, M. G., Martini, M., D’Argento, E., Forcella, C., Vita, E., Noia, V. D., Sperduti, I., Bilotta, M., Ribelli, M., Damiano, P., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.12.008 · Cited by 15 · see citing works
Mastering the Complex Targeted Therapy for Non-small Cell Lung Cancer
Devarakonda, S. H. K., Govindan, R., & Morgensztern, D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.011 · Cited by 14 · see citing works
PI3Kβ inhibition enhances ALK ‐inhibitor sensitivity in ALK ‐rearranged lung cancer
Talwelkar, S. S., Mäyränpää, M. I., Schüler, J. B., Linnavirta, N., Hemmes, A., Adinolfi, S., Kankainen, M., Sommergruber, W., Levonen, A., Räsänen, J. V., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13342 · Cited by 14 · see citing works
Co‐mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer
Xing, P., Han, X., Wang, S., Liu, Y., Yang, S., Hao, X., Wang, Y., Liu, P., Li, J., Wang, L., et al. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14565 · Cited by 14 · see citing works
Duration of Targeted Therapy in Patients With Advanced Non–small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis
Reckamp, K. L., Patil, T., Kirtane, K., Rich, T. A., Espenschied, C. R., Weipert, C. M., Raymond, V. M., Santana-Dávila, R., Doebele, R. C., & Baik, C. S. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.06.015 · Cited by 14 · see citing works
Comprehensive genomic profiling of Finnish lung adenocarcinoma cohort reveals high clinical actionability and SMARCA4 altered tumors with variable histology and poor prognosis
Talvitie, E., Liljeroos, L., Vilhonen, H., Orte, K. J., Leivo, I. V. V., Kallajoki, M. A., & Taimen, P. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100832 · Cited by 14 · see citing works

A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC).
Johnson, B. E., Kris, M. G., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Varella‐Garcia, M., Wistuba, I. I., Franklin, W. A., Ladanyi, M., Su, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8019 · Cited by 60 · see citing works
Self-citation
Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC).
Kris, M. G., Johnson, B. E., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Aronson, S. L., Engelman, J. A., Shyr, Y., Khuri, F. R., Rudin, C. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.18_suppl.cra7506 · Cited by 141 · see citing works
Self-citation
P3.03-007 LCMC2: Expanded Profiling of Lung Adenocarcinomas Identifies ROS1 and RET Rearrangements and TP53 Mutations as a Negative Prognostic Factor
Kris, M. G., Aisner, D. L., Sholl, L., Berry, L. D., Rossi, M., Chen, H., Fujimoto, J., Moreira, A., Ramalingam, S. S., Villaruz, L., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.09.1633
Self-citation
Identification of Five Driver Gene Mutations in Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan
Hsu, K.-H., Ho, C., Hsia, T., Tseng, J., Su, K., Wu, M., Chiu, K.-L., Yang, T., Chen, K.-C., Ooi, H., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120852 · Cited by 128 · see citing works
Self-citation
The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies
Greulich, H. E. (2010) · Genes & Cancer · doi:10.1177/1947601911407324 · Cited by 103 · see citing works

Authors: Aisner, D. L., Sholl, L. M., Berry, L. D., Rossi, M. R., Chen, H., Fujimoto, J., Moreira, A. L., Ramalingam, S. S., Villaruz, L. C., Otterson, G. A., Haura, E., Politi, K., Glisson, B., Cetnar, J., Garon, E. B., Schiller, J., Waqar, S. N., Sequist, L. V., Brahmer, J., Shyr, Y., Kugler, K., Wistuba, I. I., Johnson, B. E., Minna, J. D., Kris, M. G., Bunn, P. A., & Kwiatkowski, D. J.
Affiliations: University of Colorado Cancer Center (US)
Brigham and Women's Hospital (US)
Vanderbilt-Ingram Cancer Center (US)
Emory University (US)
The University of Texas MD Anderson Cancer Center (US)
Memorial Sloan Kettering Cancer Center (US)
University of Pittsburgh (US)
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
Moffitt Cancer Center (US)
Yale University (US)
Oregon Health & Science University (US)
University of California, Los Angeles (US)
The University of Texas Southwestern Medical Center (US)
Washington University in St. Louis (US)
Massachusetts General Hospital (US)
Johns Hopkins University (US)
Dana-Farber Cancer Institute (US)
Corresponding author: Aisner, Dara L.
Kwiatkowski, David J.
ORCID: Aisner, Dara L.
Sholl, Lynette M.
Berry, Lynne D.
Rossi, Michael R.
Chen, Heidi
Fujimoto, Junya
Moreira, Andre L.
Ramalingam, Suresh S.
Villaruz, Liza C.
Otterson, Gregory A.
Haura, Eric
Politi, Katerina
Glisson, Bonnie
Garon, Edward B.
Schiller, Joan
Waqar, Saiama N.
Sequist, Lecia V.
Brahmer, Julie
Shyr, Yu
Wistuba, Ignacio I.
Johnson, Bruce E.
Minna, John D.
Kris, Mark G.
Bunn, Paul A.
Kwiatkowski, David J.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2018-02-28
Volume: 24
Issue: 5
Pages: 1038-1047
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-17-2289
PMC: PMC7008001
OpenAlex: W2775798067
Cited by: 206
References: 54
Citations by year: 2026: 8 · 2025: 11 · 2024: 15 · 2023: 24 · 2022: 23 · 2021: 32 · 2020: 38 · 2019: 29 · 2018: 26
FWCI: 21.03
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Free To Breathe
National Cancer Institute (R01CA208403, P30CA008748, P30CA046934)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: lung adenocarcinoma, smoking history, TP53 mutation, targeted therapy, EGFR mutation, ALK rearrangement, ROS1 rearrangement, BRAF V600E mutation, MET amplification, survival, molecular testing, tumor suppressor, predictive biomarkers
MeSH terms: Adenocarcinoma of Lung, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, DNA Mutational Analysis, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Prognosis, Prospective Studies, Smoking, Biomarkers, Tumor, Survival Analysis, Tumor Suppressor Protein p53, Treatment Outcome, Young Adult, Molecular Targeted Therapy, High-Throughput Nucleotide Sequencing, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks